The first magnetic nanoparticle hyperthermia machine in the United States has been installed to test a new experimental treatment for advanced metastatic cancers. This technology is designed to add controlled heat to standard therapies such as chemotherapy and radiation, potentially improving their effectiveness. The treatment works in two steps. First, patients receive an IV infusion […]
The phase 3 AEWS1031 study found that in patients with nonmetastatic Ewing sarcoma treated with interval-compressed chemotherapy, the choice of local treatment—surgery, radiation, or both—did not independently affect the risk of the cancer returning in the same area. The overall 5-year local recurrence rate was low at 6%, reflecting major improvements in modern, multi-modality care.
New research shows that CDK8 and CDK19 kinases play a key role in helping ovarian cancer cells survive after detaching from the primary tumor, a process called anoikis resistance that drives metastasis. Normally, detached cells die, but resistant ovarian cancer cells survive in the peritoneal fluid, spread to other organs, and become more aggressive. The
Early results from an ongoing Phase 2 trial (NCT07222579) show that a subcutaneous (under-the-skin) form of blinatumomab (Blincyto) may be highly effective and well tolerated for mixed phenotype acute leukemia (MPAL), a rare and aggressive blood cancer. The first patient treated, a 77-year-old with Philadelphia chromosome–negative MPAL, achieved a complete response after just one 26-day
New results from the KEYMAKER-U03 substudy 03A (2026) show that several three-drug immunotherapy combinations work well as first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). The study compared the current standard treatment—pembrolizumab plus lenvatinib—with four new triplet regimens. The standard therapy had an overall response rate (ORR) of 80.6%. Adding belzutifan resulted in
New study shows that Orca-T, a high-precision donor cell therapy, can be reliably manufactured and delivered at scale. Orca-T is an investigational alternative to traditional bone marrow transplants for blood cancers such as AML, ALL, and MDS. It uses a carefully selected mix of donor immune cells to lower the risk of graft-versus-host disease (GVHD). In an
Orca-T Manufacturing Data Support Scalable Precision Transplant With Lower GVHD Rates Read More »
A new article demonstrates how FES-PET/CT is becoming an important imaging tool for estrogen receptor (ER)–positive breast cancer, especially invasive lobular carcinoma (ILC), which is often hard to detect with standard scans. ILC grows in thin “single-file” lines instead of forming clear lumps. Because of this pattern, it can be difficult to see on mammograms, ultrasound, and
A recent study examined eye side effects from mirvetuximab soravtansine-gynx (Elahere), a drug approved by the U.S. Food and Drug Administration in 2024 for platinum-resistant ovarian cancer. Eye problems usually appeared early, about five weeks after starting treatment, and most were mild to moderate, including corneal damage and blurred vision. However, researchers found an unexpected
The SWOG S1512 Phase 2 trial studied giving pembrolizumab (Keytruda) before surgery to patients with resectable desmoplastic melanoma, a rare type of skin cancer usually found on sun-exposed areas. After just three doses of pembrolizumab, 71% of patients had no cancer left in their surgical tissue samples. At three years, 74% of patients had no
Pre-Surgery Keytruda Shows Strong Results in Rare Desmoplastic Melanoma Study Read More »
Treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are moving from traditional chemoimmunotherapy (CIT) to targeted drugs. The BRUIN CLL-313 Phase III study tested pirtobrutinib, a new noncovalent Bruton tyrosine kinase inhibitor (ncBTKi), in patients who had never received treatment before. The study compared pirtobrutinib alone to bendamustine plus rituximab (BendaR), a
BRUIN CLL-313 Study: Pirtobrutinib Outperforms Chemoimmunotherapy in Frontline CLL Read More »